Glucagon – Medxy AI

SSTR2 Antagonism Restored Glucagon Responses During Experimental Hypoglycaemia in Adults With Long-Standing Type 1 Diabetes

By MedXY 05/31/2026

In a randomized crossover phase 1 study, the investigational SSTR2 antagonist ZT-01 increased glucagon responses during insulin-induced hypoglycaemia in adults with type 1 diabetes without treatment-related safety signals.

Diabetes & Endocrinology Internal Medicine news

Beta-Cell Function, Not Glucagon, Predicts Glycemic Success: A Critical Analysis of the GRADE Study

By MedXY 01/23/2026

A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting therapeutic focus should remain on beta-cell preservation.

Clinical Updates news

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

By MedXY 09/17/2025

This trial evaluates dapagliflozin's impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adjunct therapy.